Phase I trial data for remyelinating antibody in MS released
Phase I trial data for remyelinating antibody in MS released
Acorda Therapeutics has today announced safety and tolerability data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis. The trial, which followed participants for up to six months after receiving a single dose of rHIgM22, found no dose-limiting toxicities at any of the five dose levels studied. Based on this, the Company intends to advance clinical development of rHIgM22..... Read More - http://www.ms-uk.org/emergingtherapies
MS-UK - http://www.ms-uk.org/
Re: Phase I trial data for remyelinating antibody in MS rele
Science magazine has an informative article about so-called natural antibodies, including rHIgM22. Fascinating. And reminds me that we understand so so little about the immune system! http://www.sciencemag.org/content/347/6226/1058.full
-
- Similar Topics
- Replies
- Views
- Last post
-
- 2 Replies
- 290 Views
-
Last post by NHE
-
- 8 Replies
- 2033 Views
-
Last post by DIM
-
- 0 Replies
- 1416 Views
-
Last post by frodo
-
- 0 Replies
- 1645 Views
-
Last post by frodo
-
- 0 Replies
- 1317 Views
-
Last post by frodo
-
- 0 Replies
- 1735 Views
-
Last post by NHE
-
- 1 Replies
- 3185 Views
-
Last post by Tif
-
- 2 Replies
- 4413 Views
-
Last post by DIM
-
- 0 Replies
- 2529 Views
-
Last post by NHE